Title of Invention

SUPPLEMENT PREPARATION

Abstract Supplement preparation including(a),n first active component in form of biological accessible silver(b),a second active component in form of a material obtained from cartilage,and any conventional agents or additives and the use of the first and the second active component with any additional active component and'or conventional necessory agent or addition for the preparation of n health providing suppliment preparation for livesstock including thing,poultry and pig. The preparation for provent suitablefor the prevention analog and treatment of plasmacyosis,puppy doesease,enlertis virus,three day sleknes and/or "sticky" kits in mink.
Full Text WO2005/0114000 PCT/DK2004/000521
Title: Supplement preparation
Technical Field
5 The invention relatest to a prophylactic and therapeutic supplernent prepation.in
particular for animals.
Background Art
10 For competitive reasons, modem times livestock breeding, as such breeding of
furred animals and milkers, often requires large herds. This entails a high risk of in
fectious diseases, which may result in deaths and in serious cases necessitate the de-
struction of an entire herd involving heavy economic losses,
15 For preventing these situations, antibiotics are widely used, which should be consid-
ered alarming in the long view, as such a wide use furthers the development of anti-
biotic-resistant pathogenes.
In general, rational and efficient production methods are used today in modern live-
20 slock buddings, the use of which would be impossible without the use of antibiotics
for both prevention and cure. This situation is for instance typical :n poultry and pig
production.
From an ethical assessment of the animals' welfare and suffering in connection with
25 diseases, it is highly desirable to fulfil a primary health objective based on a signifi-
cant strengthening of the animal's natural immure system as defence against various
bacteria and viruses and thus allow for the removal of all antibiotics from ammal
product) on.
30 In mink breeding, problems with diseases such as plasinacytosist puppy disease
(caused by the distemper virus: canine dial a wiper vims), virus enteritis, three-day
sickness and sticky kits (diarrhoea condition found in minks during the suckling pe-

WO2005/0114000 PCT/DK2004/000521
2
nod and possibly caused by a too high lipid-to-protein ratio in the feed). Such dis-
eases often result in heavy losses and increased use of antibiotics.
Silver m a biologically accessible form, such as colloidal silver, wss commonly used
5 uritil 1938. Since then the pharmaceutical industry has taken over the field of disease
combating,mid the research on colloidal silver has been shelved in competition with
faster-acting and economically more lucrative drugs.
The therapeutic and prophylactic use of biologically accessible silver should be per-
10 formed with the utmost caution and only ra very low doses, the silver accumulating
im the organism, especially in the liver, causing, a weakening of the immune system.
Especially at prophylactic use, where silver is administered on a regular basis, it
may be difficult or practically impossible to obtain positive results without in fact
deteriorating the state of health in the long view
15
In the past 30 years, ox and shark cartilage has been used for the treatment of a num-
ber of diseases It is assumed that cartilage kills cancer cells directly, Stimulates the
immune system and inhibits the formation of new blood vessels (angiogenesis)
which the cancer cells need in order to grow uninhibited!/- A few tests are known in
20 which cartilage has been used for the treatment of cancer in humans, but the results
thereof have not been unambiguous- Shark cartilage is sold as a powder and is an
excellent source of calcium, phosphor, amino acids and mucopolysaccharides.
WO 94/] 2510 slates that in addition to the inherent nutritional benefit of shark carh-
25 lage, it is believed that two factors are also important in producing the beneficial
health effects attributed to shark cartilage. One factor is the carbohydrate or muco-
pojysaccharide content of the shark cartilage which is believed to stimulate the im-
mune system of the body to resist arid fight disease. The second iraportant fector is
the anti angiogenic factor found in the protein portion, which can contain as many as
30 five different active proteins.

WO2005/0114000 PCT/DK2004/000521
3
EP-A-I 308 155 discloses an injectable solution containing a colloid of iron and
shark cartilage-derived chondroitin sulphate. Such injecteble solution is not suitable
for a prophylactic daily use in animal breeding- Use of cofliodal silver is not sug-
gested in EP-A-1 308 155.
5
IP patent publication No 2002-145794 (application No. 2001-255278} discloses an
anti-arthritic or anti-rheumatic preparation containing art extract of the plant Withata
somnifera Dunaf combined with an extract of cartilage, such as shark cartilage.
10 In the field of health food, antimony pentasulphide (Sb3Ss, golden antimony sul-
phide) is recommended against winter coughs and bronchitis. Antimony pentasul-
phide is also used in combination with tin iodide, eg as a preparation known as
"Brorofn-adult" or -child11 The use of zinc preparations, eg, zinc isovalerate or me-
tallic zfnc, is also recommended within the field of health food.
15
The recommendations in the health food field often concern very small amounts of
the components in question, eg as a daily supplement However, in many cases, the
claimed effects are not sufficiently well documented and there has existed a wide-
spread doubtful or sceptical attitude towards the product range of the health food
20 market. Without considering whether the sceptical attitude is well founded or not, it
may be established that these materials are not among the first ones considered by
the livestock breeder for solving the above problems with infectious diseases among
livestock.
25 It has now been found that by combining biologically accessible silver with a carti-
lage preparation the positive effect of silver can be enhanced to allow the use thereof
in such low amounts that the unintended and detrimental accumulation of silver in
the organism, eg in the liver, can be avoided of reduced to a harmless level.
30 Furthermore, it has been found that by adding very small amounts of additional se-
lected components to such a silver/caitilage combination, the health-ptomoring ef-

WO2005/0114000 PCT/DK2004/000521
4
feet of this combination can be sustained.
Tt has thus been found that a preparation with a surprisingly effective prevention of
diseases, including highly infectious diseases, can be formulated by means of the
5 combination, preferably with some supplement components, which each has a
proven or presumed health-promoting effect on humans- This surprising effect has
already been seen in minks in areas with serious plasmacytosis problems. It seems to
indicate Chat the said wish to completely avoid the use of antibiotics in livestock
breeding can be fulfilled within a short time frame.
10
Brief Description of the Invention
The present invention relates to a supplement preparation including a) a first active
component in form of biologically accessible silver, b) a second active component in
15 form of a material obtained from cartilage, and any conventional accessory agents or
additives.
It is assumed that an important effect of the supplement preparation is due to the fact
th£t cartilage} such as shark cartilage, contains substances acting as catalysts on the
20 boosting of the immune system by the biologically accessible silver such that the
immune system is enhanced to a level far exceeding the effect of the individual sub-
stances. The intensifying effect has the special advantage that a positive effect can
be obtained with very modest silver amounts such that the problems with silver ac-
cumulation in the liver are avoided.
25
Moreover, it has been found that one or more different active substances, in particu-
lar such substances recommended within the homoeopathic field, directed towards
diseases causing problems among die livestock in question, advantageously may be
added to the supplement preparation- As a result, in addition to the effect on the im-
30 mune system, which provides a general improvement of the state of health of an
animal population a noticeable combating of such specific diseases is obtained.

WO2005/0114000 PCT/DK2004/000521
5
The supplement preparation may thus advantageously include one or more- addi-
tional active components. Such additional active compounds may be selected among
antimony pent a sulphide, metallic tin and/or a tin salt, metallic zinc and/or a zinc salt,
5 a sulphur containing substance and/or a iodine containing substance.
A useful sulphur containing substance is a calcium liver preparation which is com-
mercially available as "hepar- sulphuris". Examples of iodine containing substances
are tin iodide, calcium iodine and tare powder.
10
Useful active components optionally being included in the supplement preparation
are antimony pejitasulphide, metallic tin and/or a tin salt, and metallic zinc and/or a
zinc salt The tin salt may be an inorganic or an organic tin salt, preferably a tin hal-
ide such as tfn iodide- The zinc salt may be an inorganic or an organic zinc salt;
15 preferably a zinc salt of an organic caiboxylic acid as for instance zinc isovalerate
Although the actual mechanism is not yet known some of the additional active com-
ponents are inter alia believed \.o affect the liver metabolism, wbicft further prevents
silver from accumulating in the liver.
20
Colloidal silver is a suitable form of biologically accessible silver for USE as the first
component (a). A. suttahle cartilaginous material for use as the second active com
ponent (b) is a material, eg a dried powder; derived from a cartilaginous fish, pref-
25 erably a shark.
The ratio between the active components fa) and (b) in the preparation according to
the invention may vary greatly depending on the animal species and the ages of the
animals. Usually the weight ratio a:b is between 1; 100,000 and 1:10. According to a
30 preferred embodiment the content of cartilaginous material, calculated as dry matter,
is 100 - -12000parts by weight per 1 part by weight of biological accessibble silver

WO2005/0114000 PCT/DK2004/000521
6
preferably 200 - 6000 parts by weight per 1 part by weight of biologically accessible
silver and most preferably 300 - 3000 parts by weight per \ part by weight of bio-
logically accessible silver
5 Thfc contend of the biologically accessible silver may also vary greats depending ofl
the animal species and the ago of tfie animals. Usually the Ag content is between 0,1
arid 100 mg per litre preparation. According to a preferred embodiment, The prepaia-
tion contains 0.5 - 50 mg of biologically accessible silver per litre? preparation, pref-
erably 1 - 20 mg per litre.
10
The invention further relates to a uss of (a), a first active compoivent in form of bio*
logically accessible silver, (b), a second active component in form of a material de-
rived from cartilage and any additional active components and/or conventional ac-
cessory agents or additives foi I he preparation of a health-promoting supplement
15 preparation for livestock.
The extent of applicability of the invention appears from the following detailed de-
scription. It should, however, be understood that the detailed description and the
specific examples are merely included to illustrate the preferred embodiments, and
20 that various alterations and modifications within the scope of protection will be ob-
vious to persons skilled in the art on the basis of the detailed description.
Detailed Description of the Invention
15 As a base component in the preparation according to the invention biologically ac-
cessible silver is used, eg in form of colloid-dispersed silver in water, also denoted
as colloidal silver. For the prophylactic use for rninks, the silver concentration may
be about 3 mg per litre, which corresponds to 3 mg/ml. In this concentration, a daily
amount of about 8 ml per day may for instance be used in the feed for 100 bitches of
30 a weight of between 1 -2-1.8 kg, Tin's corresponds to 8 ml x 3 mg/ml = 24 fig Ag for
100 x 1.5 kg body weight per day, ie 0 16 mg Ag per kg per day.

WO2005/0114000 PCT/DK2004/000521
7
The silver content in the basic component of the preparation may vary, but is usually
chosen from between 0.5 and SO (Jg/nti. The daily dosage varies depending on the
animal species in question^ fee animaTs age, sex and general state of health, and
5 usually between Ing and 1 ng Ag per kg of body weight per day.
At present, a silver concentration in the preparation for poultry is envisaged to be -
5, preferably 2 — 3 mg/ml of silver used in a daily dosage of 0.01 - 0.21 preferably
0,09 - 0.04 ng Ag per kg body weight per day.
10
Correspondingly, for grown sows, a silver concentration in the preparation of 10 -
25, preferably 16 — 20 ug/ml of silver used in a daily dosage of 1 mg - 0.01 p.g, pref-
erably 4 - 6 ng Ag per kg body weight per day ia envisaged,
15 For mink, a silver concentration in the preparation of 0-5- 10. preferably ] -6 mg/ml
of silver used fn a daily dosage of 0.01 - 0,3 jig, preferably 0.1 - 0.4mg Ag per kg.
body weight per day is envisaged.
According to present practice, the often-recommended dosages of colloidal silver for
20 use in humans are of a level, which must be considered alarming due to the silver
accumulation m the organism- Also as regards humans, it is expected that it is possi-
ble to obtain health-promoting effects at considerably lower and safer silver dosages
by combining biologically accessible silver and a cartilaginous material The sup-
plement preparation according to the invention thus also has potential in relation to
25 humans.
The second active component, derived from cartilage, may for instance be used [n
form of a dried and ground powder obtained as a by-product from sharks in an
amount of 0.5 - 100 g per litre (= 0.5 - 100 mg/ml) in the preparation, preferably 1 -
30 g per litre. The daily doses of the cartilaginous material typically range from 1 mg
- 1 mg per tg body weight, preferably from 3 mg to 0,5 mg per kg. For mink 0.2 -

WO2005/0114000 PCT/DK2004/000521
s
0,3 mg/kg is typically used. For poultry 0.01-0-1 mg/kg is typically used, while the
daily dosages for grown sows are envisaged to range from 1 |ig to 0,0 1mg per kg. It
should, however, be noted that a too high dosage of cartilaginous material does not
have the same serious consequence as a too high silver dosage
5
In ratio lo the silver amount, the cartilage powder is preferably used in an amount of
0.05 - 12.5 g per mg Ag, more preferably in the range from 0.1 to 7.5 g per mg Ag,
and most preferably in the range from 0.5 - 4.0 gper mg Ag,
10 The combined Ag/cartiiage preparation forms a sound basis for a number of sup-
plementary active substances with health-promoting effect, in particular such sub-
stances known from the homoeopathic treatment of humans. Such substances are
available on the market and in the examples rendered below these have been identi-
fied on the basis of information received from the suppliers. In homoeopaihy, con-
15 centration specifications are used, in which for instance D6 means 1:10"6, ie. the
same as ppm. Whether such specifications denote the weight ratio (D6 = mg/kg) or
the weight/volume ratio (D6 - I mg/litre) is not always clear, nor is it always clear
whether for instance a metallic salt is calculated on the basis of the metal ion or the
entied salt molecule
20
Despite these problems, the illustrative numbers stated in the present description
provide the person skilled in the art with a guide as to advantageous amounts used at
routine adjustments of the each of the active substances to a specific animal species
or specific hards with special health problems
25
It should, however, once more be emphasized that the silver as well as many of the
possible supplementary additions are used in very small amounts,only about 1 ml of
a product with an active substance content of from D6 to D12 (1:1011) being used
for 1 litre of preparation, of which a daily addition of 4 - 8 ml to the feed for 100
30 animal being usad or for tlie treatment of individual animal merely one of two
drops being used.

WO2005/0114000 PCT/DK2004/000521
9
Examples
Colloidal silver
5 A colloid dispersion containing fine silver particles suspended in distilled water is
prepared in a conventional electro-colloid process, By using 3 mg of silver per litre a
silver dispersion of 3 mg/ml kg is obtained
Pan d'arco tea
10 A tea is prepared from paud'arco - ie. the inner bark of the tree Tabebuia avellne-
dae also known under the name of trumpet bush - by immersing a bag containing 3
g of a pau d'arco powder ("Pau d'arto Medic" supplied by BirtheKvist Andersen of
DK-9000 Aalborg) in one litre of boiling water. The mixture is left to simmer for 6
to 8 minutes whereafter the bag is removed.
Example 1
The present example described the preparation of one litre of the supplement prepa-
20 ration. The following constituents are used:

Shark cartilage powder* 7-5 g
Broron-adult** 0-9 g
Zincum val D6*** 0.4 ml
Hepar sulphauris D6**** 1.0g
Silver dispersion {3 mg/mll) quantum satis 1 litre
* "Ocean Care", which is an Australian shark cartilage powder derived from the
cold-water shark (school shark; Gakorkmus gateus) and supplied by Natural Aus-
25 tralian Import, DK-3550 Slangemp, Denmark.

WO2005/0114000 PCT/DK2004/000521
10
0.9 g of Broron-adult contains 0.9 μg active substance including antimony pen-
tasulphide and tin iodide in lactose. Broron-adult is available from Allergica Amba,
Hagemannsvej 25, DK-8600 Silkeborg.
5 *** Zincum val D6 is a zinc preparation of zinc isovalerate; it contains 1 ppm active
substance (supplier; Allergica Amba).
**** Herps: sulph. D6 is a calciumsulphar liver preparation;it contains 1 ppm of ac-
live substance; available from Allergica Amba.
10
The remaining constituents are added to the majority of the colloid silver dispersion
during stirring. Finally, the volume is adjusted to one litre with the silver dispersion-
Example 2
15
A supplement preparation for mink is prepared in the same manner as the prepara-
tion in example 1 based on the following constituents:

Paud'arco-tea 15ml
Shark cartilage powder 7.5 g
Broron-adult 0.9 g
Zincum val D6 0.4ml
Hepar sulphuris D6 l.0g
Calcium iodine D6* 0.7 ml
Stannum met D12** 0,5 ml
Juniperus comp.# 0.6 ml
Tricalcium citrate,monohydrater 0.27
Tare powder## 0.7g
Silver dispersion (3 μg/ml) quantum satis 1 litre
20 * calciurn-iodine-containing preparation containing 1 ppm of active substance;

WO2005/0114000 PCT/DK2004/000521I
11
available from Allergica Amba.
** Tin preparation (metallic tin) containing l:1012 active substance; (supplier
Allergica Amba}.
5
# Combination preparation based on Apis, Berberis vulgaris, Junipews cmmmu-
}iis, Levisticum officinalis (radix), and Arnica (honey bee, berberis, juniper
berries, lovage root and mountain tobacco) {supplied by Allergica Amba)
10 ## Tarepowder is finely pulverised tare plats (Laminaria) Tare are deep-sea
seaweed plants (kelp) with a natural iodine content of 0-5-1%.
Example 3
15 A supplement preparation for poultry is prepared in the same manner as the prepara-
tion in example 1 based on the following constituents:


Shark cartilage powder 7
Broron-adult 2.4 g
Zincum val D6 2.8 ml
Heper sulphuris D6 3.2 g
Silver dispersion (2-3 μg/m]) quantum salts 1 litre
20 For grown hens having a body weight of 2 - 3 kg 9 ml per day is typically used for
100 bens.
Example 4
25 A supplement preparation for grown sows [body weight about 250 kg) is prepared in
the same manner as the preparation in example 1 based on the following constttu-

WO2005/0114000 PCT/DK2004/000521I
12


Shark cartilage powder 12g
Broron-adult 1.3g
Zincum met D10* 1.8ml
Hepar sulphuris Dl2** 1.8 ml
Silver dispersion (18 μg/ml) quantam salts 1 litre
* Zincum met D10 is a metallic zinc preparation containing 1:10'10 of active
5 zinc, (Supplier: Allergica Atnba)
** contains l:10-12 of active substance.
7 ml per day of the supplement preparation is typically used for 3 00 sows.
10
Example 5
A base supplement preparation for livestock is prepared in the sanie manner as the
preparation in example 1 based on'the following constituents:
15


Shark cartilage powder 0.5- 30 g
Broron -adult 0.05 - 20 g
Zincum val D6 0.1-10m]
Hepar suiphuris D6 0.5-5g
Tare powder 0.3 - 20 g
Silver dispersion (1 - 40μg/ml) quantum salts 1 litre
According to need, this base preparation may be adapted to the animal species, age
and state of health by adding additional active substances.
20 Example 6

WO2005/0114000 PCT/DK2004/000521
A base supplement preparation for livestock is prepared in the same manner as the
preparation in example 1 based on the following constituents:


Shark cartilage powder 0.5- 30 g
Broron-adult 0.05-20 g
Zincum met D10 0.5-5 ml
Heparsulphuris D12 0.5-5 ml
Tare powder 0.5- 10 g
Silver dispersion (1-40 μg/ml) quantum satis 1 litre
According to need, this base preparation may be adapted to the animal species, age
and state of health by adding additional active substances.
Example 7
10
The supplement preparation made according to example 2 has been tested on a mink
farm with 300 bitches and their approx. 1500 tits. From mid April the bitches re-
ceived a daily dose of 8 ml per 100 bitches of the preparation as a supplement to the
usal feed.From june 9,the bitches received a daily dose of 8ml/100bitches,while
15 the kits received 4 ml/100 kits. On June 29 the dose was changed to 7 ml/100 ani-
mals both for bitches and for kits.
A significant improvement of the state of health was noted on the mink farm.The
kits seem heavier and more vigorous than previously. There was a lower kit mortal-
20 ity rate, more calm bitches and only a single death during the period, which is un-
usual. There were no "sticky kits" even though feed was administered according to
appetite after May 11. As beforev a few bitches stopped lactating, ie. premature
cease of milk production. This problem thus remains unsolved, but it is most likely
not linked to the immune system
25

WO2005/0114000 PCT/DK2004/000521
14
The growth of the kits was particularly good, the animals seemed to thrive optimally
and their manure was of a high quality. The latter represents a measure by means of
which deteriorations in the animals' state of health can be detected.
5 Example 8
Similar tests were carried out on three other mink farms, said tests were initiated on
May 2,2003 by administering the supplement preparation according to example 2 to
200-300 bitches per farm in a dosage of the amount as in example 6. Already in the
10 period of June 10 - 15 the test was expanded to include all animals of the three
farms, ie a total of about 7300 bitches and 37000 kits. On July 12, 2003 the manager
of the three mink farms reported:
- a significantly lower kit mortality rate from whelping to date;
15 - no cases of diarrhoea, mastitis or "sticky" Icits, the use of antibiotics has thus not
been required;
- hardly any loss of breeding bitches from whelping to date;
- no agitation or fights among 4 - 6 weeks old kits, significantly less ear sucking
and neck biting;
20 - the animals were calm with no signs of stress,
- considerably increased weight at weaning;
- peace and no Stress after weaning, no bite injuries.
- optimum use of the feed and the animals always had fine bowels movements;
- good appetite without deviations after wearing;
25 - increased growth and reduced feed consumption than normally.
Example 9
At the mink farm A the entire herd had to be destructed due to plasmacytosis.
30 Thereafter mated beaches were bought in April 2003 from the mink farm B.

WO2005/0114000 PCT/DK2004/000521
15
The animals at mink farm A and mink farm B were feed with the same type of feed
from the same supplier during The entire period until pelting with the only difference
that the animals an farm A also received the supplement preparation according to
example 2 as described in example 7,
5
The quality of the furs obtained from almost all males were estimated at the Copers
hagen Fur Center, Glosimp, Denmark and the furs were classified in five qualities
and the quality index calculated. The best quality is "Saga Royal".

Fur type Scan glow Scan' brown
Mink farm A(receiving in-ventive sup-plement) Mink farm B(without sup-plement) Mink farm A(receiving in-ventive sup-plement) Mink farm B(without sup-plement)
Saga Royal (%) 30 12 44 13
Saga (%) 53 60 46 62
A (%) 1 4 2 3
Quality I (%} 11 23 7 22
Quality II {%) 0 1 0 0
Quality Index 103 98 112 100
10
As appears in case of Scanbrown the quality of the furs from mink farm B corre-
sponds to the average quality (Index 100) among the about 2250 Danish rninkeries
supplying mink furs to Copenhagen Fur Center whereas the furs from mink farm A
with index 112 are above the 95 % fractile
15
In most cases a mink farmer selling out a part of his animals would keep the best
animals for his own breeding stock- This make the increased quality of the furs from
mink farm A it even more surprising.
20 The above description of the invention reveals that it is obvious that it can be varied
in may ways. Such variations ait not to be considered a deviation from the scope of
the invention, and all such modifications, which are obvious to persons skilled in the
art are also to be considered comprised by the scope of the succeeding claims.

WO2005/0114000 PCT/DK2004/000521
Amended claims of 11 january 2005
5 1. Supplement preparation including
a) a first active component in form of biologically accessible silver, and
b) a second active component of cartilage,
and any conventional accessory agents or additives.
10 2. Preparation according to claim lt characterised in that it includes one or more
additional active components.
3. Preparation according to claim 2, characterised in that it includes one or more
additional active components selected among antimony pentasulphide, metallic tin
15 and/or a tin salt, metallic zinc and/or a zinc salt, a sulphur containing substance
and/or a iodine containing substance.
4. Preparation according to claim 3, including hepar sulphuris as a sulphur con-
taining substance.
20
5. Preparation according to claim 3, including tare powder as a iodine containing
substance.
6. Preparation according to claim 1, characterised in that the first active compon-
25 ent (a) is a colloids silver,
7. Preparation according to claim 1, characterised in that the second active com-
ponent (b) is ground anchor dried cartilage.
30 8. preparation according to claim 1, chatactetised in tlhat the second active com




5

WO2005/0114000 PCT/DK2004/000521
My Ref:7948529
nonent (b) is obtained from a cartilaginous fish, preferably a shark-
Preparation according to claim 1, characterised in thatt the content of cartilage,
calculated as dry matter, is 100 -12,000 parts by weight per 1 part by weight of bio-
5 logically accessible silver, preferably 200 - 6000 parts by wetght per 1 part by
weight of biologically accessible silver and most preferably 300 - 3000 parts by
weight per 1 part by weight of biologically accessible silver
10 Preparation according to any one of the preceding claims, characterised in that
10 it contains 0.5 - 50 mg of biologically accessible silver per litre preparation, prefer-
ably 1 - 20 mg of si er per litre.
11. Use of (a) a first active component in form of bidogical\y accessible silver,
and (b) a second active component of cartilage, and any additional active compon-
15 ents and/or conventional accessory agents or additives for the preparation of a
health-proanoting supplement preparation for livestock.
12. Use accordingto XXX 12 of (a), a first active component in form of biologic-
ally accessible silver, and (b), a second active component of cartilage, and any addi-
20 tional active components and/or conventional accessory agent or additives for the
preparation of a preparation for the prevention and treatment of plasmacytosis,
puppy disease, emertis virus, Three-day sickness and/or "sticky" kits in mink.

Supplement preparation including(a),n first active component in form of biological accessible silver(b),a second
active component in form of a material obtained from cartilage,and any conventional agents or additives and the use of the
first and the second active component with any additional active component and'or conventional necessory agent or addition for
the preparation of n health providing suppliment preparation for livesstock including thing,poultry and pig. The preparation for
provent suitablefor the prevention analog and treatment of plasmacyosis,puppy doesease,enlertis virus,three day sleknes and/or
"sticky" kits in mink

Documents:

00101-kolnp-2006-abstract.pdf

00101-kolnp-2006-claims.pdf

00101-kolnp-2006-description complete.pdf

00101-kolnp-2006-form 1.pdf

00101-kolnp-2006-form 3.pdf

00101-kolnp-2006-form 5.pdf

00101-kolnp-2006-international publication.pdf

00101-kolnp-2006-international search authority.pdf

00101-kolnp-2006-pct forms.pdf

101-KOLNP-2006-FORM 27.pdf

101-kolnp-2006-granted-abstract.pdf

101-kolnp-2006-granted-claims.pdf

101-kolnp-2006-granted-correspondence.pdf

101-kolnp-2006-granted-description (complete).pdf

101-kolnp-2006-granted-examination report.pdf

101-kolnp-2006-granted-form 1.pdf

101-kolnp-2006-granted-form 18.pdf

101-kolnp-2006-granted-form 3.pdf

101-kolnp-2006-granted-form 5.pdf

101-kolnp-2006-granted-gpa.pdf

101-kolnp-2006-granted-reply to examination report.pdf

101-kolnp-2006-granted-specification.pdf

101-kolnp-2006-granted-translated copy of priority document.pdf


Patent Number 235024
Indian Patent Application Number 101/KOLNP/2006
PG Journal Number 26/2009
Publication Date 26-Jun-2009
Grant Date 24-Jun-2009
Date of Filing 12-Jan-2006
Name of Patentee THOMSEN JORN ODDERSHEDE
Applicant Address RAEVSKAERVEJ 21, TORNBY, DK-9850 HIRTSHALS
Inventors:
# Inventor's Name Inventor's Address
1 THOMSEN JORN ODDERSHEDE RAEVSKAERVEJ 21, TORNBY, DK-9850 HIRTSHALS
PCT International Classification Number A23K 1/175
PCT International Application Number PCT/DK2004/000521
PCT International Filing date 2004-08-02
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 PA 2003 01128 2003-08-05 Denmark